INMB — Inmune Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711754 ·
Last close
$2.03
Market Cap
$56.34M
52W High
$2.60
52W Low
$1.09
ADV30
359,230
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,476,000 | -1,273,000 | 26,845,000 | 18,411,000 | 6,483,000 |
| Mar 2026 | 0 | — | -5,812,000 | -5,407,000 | 25,818,000 | 21,358,000 | 6,194,000 |
| Dec 2025 | 0 | — | -5,474,000 | -5,264,000 | 32,351,000 | 24,751,000 | 8,827,000 |
| Sep 2025 | 0 | — | -7,433,000 | -6,472,000 | 33,358,000 | 27,734,000 | 7,980,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,961,000
Investing CF
$-336,000
Financing CF
$816,000
CapEx
$-336,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.54
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,717,000
Inventory
—
Receivables
$4,767,000
ST Investments
—
EBIT TTM
$-20,195,000
Pretax Income TTM
$-18,416,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
—
Free Cash Flow
$-10,046,875
Enterprise Value
$44,607,412
Total Cash
$18,411,000
Total Debt
$1,405,000
Shares Out
27,753,789
Trailing EPS
$-0.62
Book Value
$0.74
ROE
-74.8%
ROA
-39.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 50,000 | -30,869,000 | -45,933,000 | 32,351,000 | 8,827,000 | 23,524,000 | -22,582,000 |
| Dec 2024 | 14,000 | -42,635,000 | -42,082,000 | 39,562,000 | 7,465,000 | 32,097,000 | -33,361,000 |
| Dec 2023 | 155,000 | -29,741,000 | -30,008,000 | 57,001,000 | 18,862,000 | 38,139,000 | -11,980,000 |
| Dec 2022 | 374,000 | -25,951,000 | -27,299,000 | 81,795,000 | 21,691,000 | 60,104,000 | -22,686,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.49
Max Pain — expiry 2026-12-18
max pain strike: $2.00 · spot: $2.03 · call oi: 873 · put oi: 163
Expected Move to 2026-12-18:
±$0.53
(26.11%) —
implied range
$1.50 –
$2.56
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXOZ | EXOZYMES INC. | $57.96M | $6.24 | — |
| IMA | ImageneBio, Inc. | $53.69M | $4.72 | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | $51.65M | $15.03 | — |
| INKT | MiNK Therapeutics, Inc. | $62.15M | $12.18 | — |
| BKHA | Black Hawk Acquisition Corp | $50.96M | $12.27 | — |
News headlines (Yahoo Finance, 1h cache)
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
2026-09-14 11:00 · Yahoo
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
2026-08-26 11:00 · Yahoo
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
2026-08-07 06:11 · Yahoo
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ...
2026-08-07 05:08 · Yahoo
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
2026-08-06 20:00 · Yahoo
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
2026-07-31 11:00 · Yahoo
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
2026-07-30 11:00 · Yahoo
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
2026-07-15 11:00 · Yahoo
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
2026-07-09 11:00 · Yahoo
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
2026-06-25 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.